99% Savings - Buy Just @1 Rs X
G Kacin 250 Mg Injection is a prescription medicine that is available as a Injection. Primarily, it is used for the treatment of Urinary Tract Infection. The alternative uses of G Kacin 250 Mg Injection have also been explained below.
Medical history of the patient along with age and gender determines the dosage of G Kacin 250 Mg Injection. Besides the medical condition it is advised for, the route of administration also plays an important role in determining the correct drug dosage. Detailed information has been provided in the dosage section.
Some other side effects of G Kacin 250 Mg Injection have been listed ahead. Usually, these side effects of G Kacin 250 Mg Injection go away soon, and do not persist beyond the duration of the treatment. Please speak with your doctor if these side effects worsen or persist for a longer duration.
G Kacin 250 Mg Injection's effect during pregnancy is Severe and Unknown while nursing. It is important to know if G Kacin 250 Mg Injection has any effect on the kidney, liver and heart. Information on such adverse effects, if any, has been given in the G Kacin 250 Mg Injection related warnings section.
G Kacin 250 Mg Injection is contraindicated in people with pre-existing medical conditions like Dehydration, Parkinson's Disease, Hearing Loss as it can result in adverse effects. The section on G Kacin 250 Mg Injection contraindications lists all such conditions.
Drug interactions for G Kacin 250 Mg Injection have been reported in the medical literature. See below for a complete list.
In addition to the above precautions for G Kacin 250 Mg Injection, it is important to know that it is safe while driving, and is habit-forming.
G Kacin 250 Mg Injection is used to treat the following -
Main Benefits
Other Benefits
This is the usual dosage recommended in most common treatment cases. Please remember that every patient and their case is different, so the dosage can be different based on the disease, route of administration, patient's age and medical history.
Find the right dosage based on disease and age
Age Group | Dosage |
Adult |
|
Geriatric |
|
13 - 18 years (Adolescent) |
|
Infant (1 month to 2 years) |
|
Neonates (0 to 1 month) |
|
2 - 12 years (Child) |
|
Is the use of G Kacin 250 Mg Injection safe for pregnant women?
G Kacin should not be taken during pregnancy, or should only be taken on the advice of a doctor as it may have severe side effects.
Is the use of G Kacin 250 Mg Injection safe during breastfeeding?
Information about safety of G Kacin for women who are breastfeeding is not available since scientific research on this is yet to be done.
What is the effect of G Kacin 250 Mg Injection on the Kidneys?
Consumption of G Kacin can harm the kidneys. So it is important to take medical advice beforehand.
What is the effect of G Kacin 250 Mg Injection on the Liver?
Very few cases of side effects of G Kacin on the liver have been reported.
What is the effect of G Kacin 250 Mg Injection on the Heart?
G Kacin has very mild side effects on the heart.
If you are suffering from any of the following diseases, you should not take G Kacin 250 Mg Injection unless your doctor advises you to do so -
Is this G Kacin 250 Mg Injection habit forming or addictive?
G Kacin 250 Mg Injection is not addictive in nature.
Is it safe to drive or operate heavy machinery when consuming?
Yes, you can comfortably use machinery or drive after taking G Kacin 250 Mg Injection since it will not make you feel sleepy.
Is it safe?
G Kacin 250 Mg Injection should be used only after doctor's advice.
Is it able to treat mental disorders?
No, G Kacin 250 Mg Injection cannot treat any kind of mental disorder.
Interaction between Food and G Kacin 250 Mg Injection
It is safe to take G Kacin 250 Mg Injection with food.
Interaction between Alcohol and G Kacin 250 Mg Injection
Due to lack of research, nothing can be said about side effects of consuming alcohol while taking G Kacin 250 Mg Injection.
Yes, G Kacin has been reported to cause diarrhoea and it is a common side effect of this medicine. Drink plenty of fluids while you are taking this medicine. If you are experiencing severe diarrhoea after using this drug, discuss with your doctor immediately without any further delay.
Yes, G Kacin has been reported to cause ototoxicity (hearing loss or deafness) which is irreversible and may progress after discontinuation of the drug. It is a common side effect of this medicine. If you experience hearing loss or deafness after consuming or applying for this medicine, then consult your doctor and follow his/her instructions.
No, G Kacin is not available in tablet form. It is available in only injectable dosage form either given by intramuscularly or intravenously depends on patient condition or severity of infections.
No, G Kacin cannot be taken with penicillin. Because penicillin inactivates the G Kacin by combining the beta-lactam ring of penicillin with an amino group of this drug to form amide which is biologically inactive. For this reason G Kacin should not be taken with penicillin. The chances of inactivation of this drug are higher in case of renal failure because in this case concentration of penicillin is higher in the kidney for a longer time as compared to the normal renal function.
G Kacin is a broad-spectrum antibiotic which is active against both Gram-positive and Gram-negative bacteria. It works by preventing the synthesis of proteins that bacteria need to survive, in the absence of protein synthesis bacteria become vulnerable and dies. It is effective against different types of bacteria such as Escherichia coli, Proteus species, S. aureus, Acinetobacter and Serratia species.
This medicine data has been created by -
B.Pharma, Pharmacy
5 Years of Experience
References
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Arikayce (amikacin)
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 749
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 136-137